Osteopore gets exclusive license for bone and tissue regeneration tech
Australian-Singaporean regenerative medicine company Osteopore (ASX: OSX) has secured an exclusive licensing agreement with Accelerate for a pioneering Heparan Sulphate bioactive technology platform.











